Search results for "Registries"

showing 5 items of 615 documents

Hip viscosupplementation under ultra-sound guidance riduces NSAID consumption in symptomatic hip osteoarthritis patients in a long follow-up. Data fr…

2011

Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) consumption is strictly related to a high gastrointestinal and cardiovascular mortality and morbidity rate. Osteoarthritis Research Society International (OARSI) recommendations in patients with symptomatic hip or knee OA stated that NSAIDs should be used at the lowest effective dose but their long-term use should be avoided if possible. OARSI guidelines for the treatment of the hip OA include the use of viscosupplementation, which aims to restore physiological and rheological features of the synovial fluid. Objective: Aim of this multicentric, open and retrospective study is to investigate if NSAID consumption may be reduced by t…

musculoskeletal diseaseshipultrasoundintra-articular injection; nsaid; hyaluronic acid; hip; ultrasound; osteoarthritisAnti-Inflammatory Agents Non-SteroidalMiddle AgedHip viscosupplementation ultra-sound guidanceOsteoarthritis HipInjections Intra-ArticularosteoarthritisSettore MED/33 - Malattie Apparato LocomotoreHumansUltrasonicsRegistriesHyaluronic Acidnsaidintra-articular injectionAgedFollow-Up StudiesPain MeasurementRetrospective StudiesUltrasonography
researchProduct

The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

2017

BACKGROUND: GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non-vitamin K antagonist oral anticoagulant (NOAC), became available.OBJECTIVES: This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1.METHODS: During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis des…

oral anticoagulationCross-Sectional StudieMaleRegistrieFibrinolytic AgentInternationalityAntithrombinMedizinregistryMiddle AgedAntithrombinsDabigatranStrokeProspective StudieCross-Sectional StudiesFibrinolytic AgentsAtrial FibrillationJournal ArticleHumansFemaleProspective StudiesRegistriesCardiology and Cardiovascular MedicineAgedHuman
researchProduct

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in De…

2020

Background: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. Objective: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. Methods: The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. Results: O…

safetyAdultMalemedicine.medical_specialtyTime Factorsbiologic agentsprospective cohortlong-term follow-upDermatologyimmunosuppressive agentsanti-inflammatory agentsCohort Studies030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinePsoriasisUstekinumabmedicineAdalimumabHumansPsoriasisRegistriesAdverse effectProspective cohort studyAgedbusiness.industryregistriespsoriasis/drug therapyanti-TNFMiddle Agedmedicine.diseaseInfliximabBiological TherapySpain030220 oncology & carcinogenesispharmacovigilanceadverse effectsSecukinumabFemaleApremilastbusinessmedicine.drugJournal of the American Academy of Dermatology
researchProduct

Percutaneous Recanalization of Chronic Total Occlusions : 2019 Consensus Document from the EuroCTO Club

2019

Since its inception in December 2006, the EuroCTO Club has strived to provide the framework for state-of-the-art chronic total occlusion (CTO) percutaneous coronary intervention (PCI) in Europe and nearby regions. Among its initiatives, the EuroCTO Club has published a set of recommendations regarding the technical aspects of CTO PCI, whose last edition dates to 2012. The EuroCTO Club consensus document discusses CTO PCI clinical indications, techniques and equipment use, as well as the qualifications of operators/centres. Given the considerable amount of progress made by this subspecialty in recent years, there is a need for an updated document that includes data from recent clinical trial…

stable anginaPercutaneousConsensusmedicine.medical_treatmentMEDLINE030204 cardiovascular system & hematologySubspecialtyCoronary AngiographyTotal occlusion03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionPercutaneous Coronary Intervention.drug-eluting stentMedicineHumans030212 general & internal medicineRegistrieschronic total occlusionbusiness.industryPercutaneous coronary interventionmedicine.diseaseClinical trialEuropeTreatment OutcomeCoronary OcclusionConventional PCIChronic DiseaseClubMedical emergencyCardiology and Cardiovascular Medicinebusiness
researchProduct

Radiation Exposure for Percutaneous Interventions of Chronic Total Coronary Occlusions in a Multicenter Registry: The Influence of Operator Variabili…

2021

Aims. Radiation exposure is a limiting factor for percutaneous coronary interventions (PCI) of chronic total coronary occlusion (CTO) lesions. This study was designed to analyze changes in patient radiation dose for CTO-PCI and parameters associated with radiation dose. Methods and Results. We analyzed a cohort of 12,136 procedures performed by 23 operators between 2012 and 2017 from the European Registry of CTO-PCI. Radiation exposure was recorded as air kerma (AK) and dose area product (DAP). A dose rate index (DRI) was calculated as AK per fluoroscopy time to normalize for individual differences in fluoroscopy time. The lesion complexity increased from Japanese-CTO (J-CTO) score of 2.19 …

stable anginapercutaneous coronary interventionchronic coronary total occlusionRadiation ExposureCoronary AngiographyTreatment OutcomeCoronary OcclusionRisk FactorsFluoroscopyChronic DiseaseHumansRegistriesradiation protection
researchProduct